Home > Cardiology > ACC/WCC 2020 > Heart Failure and Cardiomyopathies > Mavacamten shows promising results in non-obstructive hypertrophic cardiomyopathy

Mavacamten shows promising results in non-obstructive hypertrophic cardiomyopathy

Presented By
Dr Carolyn Y. Ho, Brigham and Women's Hospital, USA
Conference
ACC 2020
Trial
Phase 2, MAVERICK-HCM
Results from the phase 2 MAVERICK-HCM trial showed that treatment with mavacamten in patients with non-obstructive hypertrophic cardiomyopathy was well tolerated and reduced biomarkers of cardiac injury and wall stress, according to Dr Carolyn Y. Ho (Brigham and Women's Hospital, USA) [1]. Mavacamten is a first-in-class, selective allosteric inhibitor of cardiac myosin, which reduces the number of myosin-actin cross bridges and decreases the excessive contractility that characterises hypertrophic cardiomyopathy. The MAVERICK-HCM study analysed 59 patients with symptomatic non-obstructive hypertrophic cardiomyopathy. After a 28-day screening period, patients were assigned to either once-daily mavacamten with a drug concentration target of 200 ng/mL (n=19), once-daily mavacamten with a drug concentration target of 500 ng/...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on